New Triple-Threat treatment trial launches for tough ovarian cancer cases
NCT ID NCT07261683
Summary
This study is testing whether combining three drugs—paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—can help control recurrent ovarian cancer. It aims to see if this combination shrinks tumors and is safe for patients. The trial will involve about 20 adults whose cancer has returned after initial treatment. Participants will receive the drugs on a set schedule and be closely monitored for their response and any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Obstetrics and Gynecology Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200090, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.